Registry of patients with connective tissue diseases and lung issues
Connective Tissue Diseases and Lung Manifestations Prospective Trial With Focus on Systemic Sclerosis (Colipris)
This study is collecting health information from patients with connective tissue diseases to see how often they develop lung problems and to understand their treatment over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Medical University Innsbruck Academic / other |
| Locations | 1 site (Innsbruck) |
| Trial ID | NCT04095351 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to collect comprehensive clinical data on the incidence, prevalence, and progression of interstitial lung disease (ILD) and pulmonary hypertension (PH) in patients with connective tissue diseases (CTD) in Western Austria. Over a period of 10 years, the study will gather demographic information, clinical data, laboratory values, and therapeutic management details. Additionally, blood samples will be collected from a subgroup of patients with systemic sclerosis for translational research to explore inflammatory and fibrotic patterns. The goal is to better understand the disease course and identify potential therapeutic interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients aged 18 and older diagnosed with connective tissue diseases.
Not a fit: Patients with serious co-morbidities that interfere with the course of interstitial lung disease or pulmonary hypertension may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and treatment strategies for patients with connective tissue diseases and associated lung manifestations.
How similar studies have performed: While there have been previous studies on this topic, this registry aims to fill gaps in understanding the epidemiology and management of ILD and PH in CTD patients, making it a potentially novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The inclusion criteria are adult patients (≥18 years) diagnosed with CTD with signed informed consent. Exclusion Criteria: * Exclusion criteria are patients with a serious co-morbidity interfering with the course of interstitial lung disease or pulmonary hypertension.
Where this trial is running
Innsbruck
- Medical University Innsbruck, Department of Internal Medicine II — Innsbruck, Austria (Recruiting)
Study contacts
- Principal investigator: Judith Löffler-Ragg, Prof. MD — Medical University Innsbruck, Department Internal Medicine
- Study coordinator: Magdalena Aichner, MD
- Email: magdalena.aichner@i-med.ac.at
- Phone: +43 512-504-83765
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.